Actively Recruiting
Phase 2 Study Evaluating INCB123667 in Women With Platinum-Resistant Ovarian Cancer and Cyclin E1 Overexpression
Led by Incyte Corporation · Updated on 2026-09-15
160
Participants Needed
74
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of INCB123667 in people with platinum-resistant ovarian cancer who show high levels of Cyclin E1 in their tumors. This phase 2, single-arm study focuses on this specific group to better understand how the drug works for this challenging condition. Participants will receive INCB123667 orally twice daily. The dose will be based on the level of Cyclin E1 expression in their tumors as defined by the study protocol. The study includes several groups receiving the same treatment under these tailored dosing guidelines. Throughout the study, participants will be monitored for tumor response, progression-free survival, overall survival, and any treatment side effects for up to two years. Regular assessments including biopsies, imaging, and safety evaluations will be conducted to track treatment effects and patient health during this period.
CONDITIONS
Brief Title
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here